Drug Profile
Prosaptide TX14 A
Alternative Names: Prosaposin-derived peptide; Prosaptide™Latest Information Update: 26 Mar 2008
Price :
$50
*
At a glance
- Originator Myelos Corporation
- Class Analgesics; Nerve growth factors
- Mechanism of Action Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies; Neuropathic pain
Most Recent Events
- 26 Mar 2008 Discontinued - Phase-II for Neuropathic pain in USA (SC)
- 12 Jan 2006 Development of prosaptide TX14 A has been discontinued
- 11 Mar 2005 Discontinued - Phase-II for Neuropathic pain in USA (unspecified route)